Vasculature News and Research

RSS

Tips offered in April 2010 issue of American Journal Of Pathology

A group led by Dr. Massimo Loda at the Dana Farber Cancer Institute, Boston, MA has generated a preclinical model of human prostate cancer that mimics the genetic and growth behavior of primary tumors. Their report can be found in the April 2010 issue of the American Journal of Pathology.

25 Mar 2010

InnerPulse selects Dassault Systemes' Abaqus FEA software

Dassault Systèmes, a world leader in 3D and Product Lifecycle Management (PLM) solutions, today announced that InnerPulse, a medical device company pioneering a novel technology for those patients with cardiac rhythm disorders, has selected Abaqus finite element analysis (FEA) software from the SIMULIA to assist in development of their technology designed in SolidWorks CAD software.

16 Mar 2010

U.S. Vascular Access Holdings acquires National Vascular Care

Fresenius Medical Care, the world’s largest provider of dialysis services and products, today announced that its subsidiary, U.S. Vascular Access Holdings, LLC has completed the acquisition of National Vascular Care Inc.

4 Mar 2010

SEBM announces the 2010 winners of Young Investigator Award

SEBM is pleased to announce the 2010 winners of the Young Investigator Award. This is a $500 travel grant for undergraduate/ graduate students and/or individuals within 5 years of receiving doctoral degrees who are members of the Society to attend the Experimental Biology 2010 meeting in Anaheim in April 2010.

4 Mar 2010

SNI clinical study using ultrasound for treatment of ICH and IVH presented at International Stroke Conference

EKOS Corporation announced today that Dr. David W. Newell, Co–Executive Director, Swedish Neuroscience Institute (Seattle, WA) presented a SNI clinical study known as ‘SLEUTH’ (Safety of Lysis with Ultrasound in the Treatment of Intracerebral (ICH) and Intraventricular Hemorrhage (IVH) at the American Heart Association International Stroke Conference (San Antonio, TX).

26 Feb 2010

TMI's Glider balloon catheter for PTA of lesions in peripheral vasculature receives FDA marketing clearance

TriReme Medical, Inc. (TMI) announced today that it has received FDA clearance for its newest product, the Glider™ balloon catheter, for percutaneous transluminal angioplasty (PTA) of lesions in the peripheral vasculature including the iliac, femoral, ilio-femoral, popliteal, infra-popliteal, and renal arteries.

25 Feb 2010

YM BioSciences-Cytopia merger complete

YM BioSciences Inc., announced that the merger of Cytopia Limited, the Australian biopharmaceutical company, into YM under a Scheme of Arrangement, has been concluded.

1 Feb 2010

Update on Cardium Therapeutics' plans for commercial development of Generx

Cardium Therapeutics reported today that its Cardium Biologics division provided an update on plans for the continuing commercial development of Generx™ (alferminogene tadenovec, Ad5FGF-4), a DNA-based angiogenic therapy product candidate for patients with coronary artery disease.

27 Jan 2010

Study lays groundwork to develop new treatments for cardiovascular disease and other conditions

In a significant step toward restoring healthy blood circulation to treat a variety of diseases, a team of scientists at Weill Cornell Medical College has developed a new technique and described a novel mechanism for turning human embryonic and pluripotent stem cells into plentiful, functional endothelial cells, which are critical to the formation of blood vessels.

21 Jan 2010

Study: Heart's ability to pump effectively is diminished among people with common lung disease

A new study from Columbia University Medical Center researchers, has found that the heart's ability to pump effectively is diminished among people with a common lung disease, even in people with no or mild symptoms.

21 Jan 2010

Cook Medical presents latest advancements at ISET 2010 International Symposium on Endovascular Therapy

Signaling its continued commitment to addressing the anatomy of the entire peripheral vasculature and combating disease with targeted diagnostic and interventional devices, Cook Medical is presenting its latest advancements at the ISET 2010 International Symposium on Endovascular Therapy.

20 Jan 2010

Bevacizumab drug shows promise to slow tumor growth in lung cancer patients

Phase II study results of the agent ASA404 showed promise in patients with either squamous or non-squamous non-small cell lung cancer (NSCLC).

13 Jan 2010

Stem cell therapy holds promise as potential alternative to bone grafting operations

A study published this week reinforces the potential value of stem cells in repairing major injuries involving the loss of bone structure.

12 Jan 2010

New therapeutic treatment may provide a potential alternative to bone grafting operation

A study published this week reinforces the potential value of stem cells in repairing major injuries involving the loss of bone structure.

12 Jan 2010

Cardima receives Shonin approval from the Japanese MHLW to market PATHFINDER catheters

Cardima, Inc., a medical device company focused on the diagnosis and treatment of atrial fibrillation (AF), has received Shonin approval from the Japanese Ministry of Health, Labour and Welfare (MHLW) to re-enter the Japanese market with its family of guidewire-based, multi-electrode PATHFINDER® diagnostic mapping catheters.

4 Jan 2010

AngioDynamics introduces new family of micro-introducer kits with stiffened introducer option

AngioDynamics today announced the launch of a new family of micro-introducer kits, featuring a stiffened introducer option.

30 Dec 2009

Researchers use hydrogels to induce significant vasculature growth in areas of damaged tissue

Regenerative medicine therapies often require the growth of functional, stable blood vessels at the site of an injury. Using synthetic polymers called hydrogels, researchers at the Georgia Institute of Technology have been able to induce significant vasculature growth in areas of damaged tissue.

22 Dec 2009

Acceleron Pharma's ACE-536 stimulates red blood cell production through novel mechanism

Acceleron Pharma, Inc., a biopharmaceutical company developing novel therapeutics that modulate the growth of cells and tissues including red blood cells, bone, muscle, fat, and the vasculature, presented data demonstrating that ACE-536 promotes formation of red blood cells through inhibition of members of the TGF-beta superfamily, at the 51st Annual Meeting of the American Society of Hematology.

8 Dec 2009

Acceleron Pharma announces study results of its ACE-011 and ACE-536 blood forming agents

Acceleron Pharma, Inc., a biopharmaceutical company developing novel therapeutics that modulate the growth of cells and tissues including red blood cells, bone, muscle, fat, and the vasculature, today announced that results from preclinical and clinical studies of two, novel blood forming agents, ACE-011 and ACE-536, will be presented at the 51st Annual Meeting of the American Society of Hematology at the Ernest N. Morial Convention Center in New Orleans, Louisiana.

1 Dec 2009

Experiments explain factors behind common malarial symptoms

When people have malaria, they are infected with Plasmodium parasites, which enter the body from the saliva of a mosquito, infect cells in the liver, and then spread to red blood cells. Inside the blood cells, the parasites replicate and also begin to expose adhesive proteins on the cell surface that change the physical nature of the cells in the bloodstream.

23 Nov 2009